Proteom Capital - using genetic engineering techniques in investment analysis  Home search sitemap contact us
 
about proteom press funds performance people investors   
Using the power of computational biology to navigate financial markets

 

 
 search Proteom

background

Proteom has developed a highly successful proprietary investment program based on research by econometrician

Dr Jonathan Kinlay  which identifies volatility arbitrage opportunities.

The gene sequencing research by Dr Haftan Eckholdt at Albert Einstein College of Medicine, NYC, has spawned new techniques for investment analysis.

 

Proteom

Proteom Capital Management Ltd offers sophisticated quantitative investment strategies using proprietary, state-of-the-art econometric and bioengineering technologies developed in conjunction with the research and consulting firm Investment Analytics
 

news

  • Dr Kinlay is speaking on asset volatility modeling and trading at the Quant USA conference in New York on July 14, 2009.

 
 

fund performance

 

'08

 

 

Equity Stat. Arb.
 

Global Equity L/S

 

 

 

+12.17%
 

+8.06%

Disclaimer:  The material on this web site is for informational purposes only.  An investment in the Proteom Fund is not available to the public. 

 

 
Copyright © 2003-2006 Proteom Capital Management Ltd. All rights reserved.